DoseWire: OSL signs exclusive distributor agreement with DoseVue NV
13th July 2021
Oncology Systems Limited (OSL) would like to announce they have signed an exclusive agreement with DoseVue NV, to distribute an in-vivo dosimetry product DoseWire ™ Series 200, to radiotherapy centres within the UK and Ireland.
DoseVue’s unique technology uses fibre optic filaments coated in a light-emitting material that fluoresces when exposed to radiation. This allows for the real-time, accurate measurement of the actual dose delivered during radiation oncology procedures. The compact sensors of the DoseWire™ Series 200 can be easily positioned at up to four locations during procedures, applied on patient’s skin or introduced in natural and/or surgical cavities. CE marked as a medical device, the DoseWire™ Series 200 can be used for a range of applications, including brachytherapy and intraoperative radiation therapy (IORT).
“OSL are proud to be offering this unique and innovative technology for in-Vivo Dosimetry. DoseWire is suitable for multiple applications with fibre optic precision and accuracy. A great addition to our portfolio”, adds Stuart Southgate, Commercial Manager, OSL.
The DoseWire Series 200 has been validated in the following clinical contexts:
- HDR Brachytherapy (using lr-192)
- Electron-based IORT
- MRI Linac (6 MeV, 0.4 T maximum)
- Stereotactic Radiosurgery
- Contact therapy (Orthovoltage therapy)
- Proton therapy (up to 62 MeV)
Contact OSL to find out more about the DoseWire Series 200.